Inhibition of type 1 17β-hydroxysteroid dehydrogenase impairs the synthesis of 17β-estradiol in endometriosis lesions

Journal of Clinical Endocrinology and Metabolism

Volumn 99, Issue 1, 2014, Pages 276-284

  Delvoux, Bert ^a   D'Hooghe, Thomas ^c   Kyama, Cleophas ^c   Koskimies, Pasi ^d   Hermans, Rob J J ^b   Dunselman, Gerard A ^a   Romano, Andrea ^a  

^a MAASTRICHT UNIVERSITY   (Netherlands)

^b MAASTRICHT UNIVERSITY   (Netherlands)

^c UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^d Forendo Pharma Ltd   (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

ESTRADIOL; TESTOSTERONE 17BETA DEHYDROGENASE;

ARTICLE; CLINICAL ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; ENDOMETRIOSIS; ENDOMETRIUM BIOPSY; ENZYME ACTIVITY; ENZYME ANALYSIS; ENZYME INHIBITION; ESTROGEN METABOLISM; ESTROGEN SYNTHESIS; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN TISSUE; METABOLIC DISORDER; PRIORITY JOURNAL; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION;

17-HYDROXYSTEROID DEHYDROGENASES; CELLS, CULTURED; ENDOMETRIOSIS; ENDOMETRIUM; ENZYME INHIBITORS; ESTRADIOL; FEMALE; HUMANS; INTESTINAL DISEASES; OVARIAN DISEASES; PERITONEAL DISEASES; RNA, MESSENGER;

EID: 84892172244     PISSN: 0021972X     EISSN: 19457197     Source Type: Journal    
DOI: 10.1210/jc.2013-2851     Document Type: Article

References (41)

1. Giudice LC. Clinical practice. Endometriosis. N Engl J Med. 2010; 362:2389-2398.
2. Nap AW, Groothuis PG, Demir AY, Evers JL, Dunselman GA. Pathogenesis of endometriosis. Best Pract Res Clin Obstet Gynaecol. 2004;18:233-244.
3. Simoens S, Dunselman G, Dirksen C, et al. The burden of endometriosis: costs and quality of life of women with endometriosis and treated in referral centres. Hum Reprod. 2012;27:1292-1299.
4. Simoens S, Hummelshoj L, Dunselman G, Brandes I, Dirksen C, D'Hooghe T. Endometriosis cost assessment (the Endo Cost study): a cost-of-illness study protocol. Gynecol Obstet Invest. 2011;71:170-176.
5. Simoens S, Hummelshoj L, D'Hooghe T. Endometriosis: cost estimates and methodological perspective. Hum Reprod Update. 2007; 13:395-404.
6. Rogers PA, D'Hooghe TM, Fazleabas A, et al. Priorities for endometriosis research: recommendations from an international consensus workshop. Reprod Sci. 2009;16:335-346.
7. Nyholt DR, Low SK, Anderson CA, et al. Genome-wide association meta-analysis identifies new endometriosis risk loci. Nat Genet. 2012;44:1355-1359.
8. de Graaff AA, Dunselman GA, Delvoux B, van Kaam KJ, Smits LJ, Romano A. B lymphocyte stimulator -817C>T promoter polymorphism and the predisposition for the development of deep infiltrating endometriosis. Fertil Steril. 2010;94:1108-1110.
9. Huhtinen K, Stahle M, Perheentupa A, Poutanen M. Estrogen biosynthesis and signaling in endometriosis. Mol Cell Endocrinol. 2012;358:146-154.
10. Delvoux B, Groothuis P, D'Hooghe T, Kyama C, Dunselman G, Romano A. Increased production of 17β-estradiol in endometriosis lesions is the result of impaired metabolism. J Clin Endocrinol Metab. 2009;94:876-883.
11. Rizner TL. Estrogen metabolism and action in endometriosis. Mol Cell Endocrinol. 2009;307:8-18.
12. Groothuis PG, Nap AW, Winterhager E, Grummer R. Vascular development in endometriosis. Angiogenesis. 2005;8:147-156.
13. Ferrero S, Venturini PL, Ragni N, Camerini G, Remorgida V. Pharmacological treatment of endometriosis: experience with aromatase inhibitors. Drugs. 2009;69:943-952.
14. Brown J, Kives S, Akhtar M. Progestagens and anti-progestagens for pain associated with endometriosis. Cochrane Database Syst Rev. 2012;3:CD002122.
15. Laschke MW, Menger MD. Anti-angiogenic treatment strategies for the therapy of endometriosis. Hum Reprod Update. 2012;18:682-702.
16. Moeller G, Adamski J. Integrated view on 17β-hydroxysteroid dehydrogenases. Mol Cell Endocrinol. 2009;301:7-19.
17. Day JM, Foster PA, Tutill HJ, et al. 17β-hydroxysteroid dehydrogenase type 1, and not type 12, is a target for endocrine therapy of hormone-dependent breast cancer. Int J Cancer. 2008;122:1931-1940.
18. Mindnich R, Adamski J. Functional aspects of 17β-hydroxysteroid dehydrogenase 1 determined by comparison to a closely related retinol dehydrogenase. J Steroid Biochem Mol Biol. 2007;104:334-339.
19. Schenken RS, Guzick DS. Revised endometriosis classification: 1996. Fertil Steril. 1997;67:815-816.
20. Noyes RW, Hertig AT, Rock J. Dating the endometrial biopsy. Am J Obstet Gynecol. 1975;122:262-263.
21. Cornel KM, Kruitwagen RF, Delvoux B, et al. Overexpression of 17β-hydroxysteroid dehydrogenase type 1 increases the exposure of endometrial cancer to 17β-estradiol. J Clin Endocrinol Metab. 2012;97:E591-E601.
22. Delvoux B, Husen B, Aldenhoff Y, et al. A sensitive HPLC method for the assessment of metabolic conversion of estrogens. J Steroid Biochem Mol Biol. 2007;104:246-251.
23. Messinger J, Husen B, Koskimies P, et al. Estrone C15 derivatives- a new class of 17β-hydroxysteroid dehydrogenase type 1 inhibitors. Mol Cell Endocrinol. 2009;301:216-224.
24. Arnold C, Einspanier A. Medical treatment improves social behav ior in a primate endometriosis model (Callithrix jacchus). J Med Primatol. 2013;42:112-119.
25. Husen B, Huhtinen K, Poutanen M, Kangas L, Messinger J, Thole H. Evaluation of inhibitors for 17β-hydroxysteroid dehydrogenase type 1 in vivo in immunodeficient mice inoculated with MCF-7 cells stably expressing the recombinant human enzyme. Mol Cell Endocrinol. 2006;248:109-113.
26. Lamminen T, Saloniemi T, Huhtinen K, et al. In vivo mouse model for analysis of hydroxysteroid (17β) dehydrogenase 1 inhibitors. Mol Cell Endocrinol. 2009;301:158-162.
27. Saloniemi T, Jarvensivu P, Koskimies P, et al. Novel hydroxysteroid (17β) dehydrogenase 1 inhibitors reverse estrogen-induced endometrial hyperplasia in transgenic mice. Am J Pathol. 2010;176:1443-1451.
28. Akaike H. Information theory and extension of the maximum likelihood principle. In: Petrov BN, Csaki F, eds. Second International Symposium on Information Theory. Budapest, Hungary: Akademia Kiado; 1973:267-281.
29. Huhtinen K, Desai R, Stahle M, et al. Endometrial and endometriotic concentrations of estrone and estradiol are determined by local metabolism rather than circulating levels. J Clin Endocrinol Metab. 2012;97:4228-4235.
30. Dassen H, Punyadeera C, Kamps R, et al. Estrogen metabolizing enzymes in endometrium and endometriosis. Hum Reprod. 2007; 22:3148-3158.
31. Purohit A, Fusi L, Brosens J, Woo LW, Potter BV, Reed MJ. Inhibition of steroid sulphatase activity in endometriotic implants by 667 COUMATE: a potential new therapy. Hum Reprod. 2008;23:290-297.
32. Colette S, Defrere S, Lousse JC, Van Langendonckt A, Gotteland JP, Loumaye E, Donnez J. Inhibition of steroid sulfatase decreases endometriosis in an in vivo murine model. Hum Reprod. 2011;26:1362-1370.
33. Colette S, Lousse JC, Defrere S, et al. Absence of aromatase protein and mRNA expression in endometriosis. Hum Reprod. 2009;24:2133-2141.
34. Lepine J, Audet-Walsh E, Gregoire J, et al. Circulating estrogens in endometrial cancer cases and their relationship with tissular expression of key estrogen biosynthesis and metabolic pathways. J Clin Endocrinol Metab. 2010;95:2689-2698.
35. Aghajanova L, Hamilton A, Kwintkiewicz J, Vo KC, Giudice LC. Steroidogenic enzyme and key decidualization marker dysregulation in endometrial stromal cells from women with versus without endometriosis. Biol Reprod. 2009;80:105-114.
36. Ferrero S, Gillott DJ, Venturini PL, Remorgida V. Use of aromatase inhibitors to treat endometriosis-related pain symptoms: a systematic review. Reprod Biol Endocrinol. 2011;9:89.
37. Purohit A, Foster PA. Steroid sulfatase inhibitors for estrogen- and androgen-dependent cancers. J Endocrinol. 2012;212:99-110.
38. Kennedy S, Bergqvist A, Chapron C, et al. ESHRE guideline for the diagnosis and treatment of endometriosis. Hum Reprod. 2005;20:2698-2704.
39. Luu-The V, Labrie F. The intracrine sex steroid biosynthesis pathways. Prog Brain Res. 2010;181:177-192.
40. Poirier D. Contribution to the development of inhibitors of 17β-hydroxysteroid dehydrogenase types 1 and 7: key tools for studying and treating estrogen-dependent diseases. J Steroid Biochem Mol Biol. 2011;125:83-94.
41. Day JM, Tutill HJ, Purohit A, Reed MJ. Design and validation of specific inhibitors of 17β-hydroxysteroid dehydrogenases for therapeutic application in breast and prostate cancer, and in endometriosis. Endocr Relat Cancer. 2008;15:665-692.